metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
versus ipilimumab alone
	nivolumab alone vs. ipilimumab alone	1			-
	nivolumab plus ipilimumab vs. ipilimumab alone	2			-
versus ipilimumab followed by nivolumab
	nivolumab followed by ipilimumab vs. ipilimumab followed by nivolumab	1		-	-
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1			-
	relatlimab plus nivolumab vs. nivolumab alone	1	-		-
versus Standard of Care (SoC)
	tremelimumab vs. Standard of Care (SoC)	1		-	-